Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). If approved, exa-cel would be the only genetic therapy for.

Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex's VX-548 shows promising efficacy and safety in neuropathic pain management, potentially outperforming Lyrica. Q3 financials are strong: 6% revenue growth, 87.16% gross profit margin, driven by Cystic Fibrosis treatments. VX-548's market potential is significant, with projected sales over $5 billion, enhancing Vertex's revenue streams.

Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles

Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.

Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data

Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Vertex (VRTX) Soars 13.2%: Is Further Upside Left in the Stock?

Arcturus Therapeutics

Novo Nordisk

With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and how we can improve functioning within the body.

3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024

Vertex Pharmaceuticals (VRTX) shares hit at an all-time high Wednesday after reporting promising results from a study of its experimental treatment to reduce pain in diabetics, and striking a deal for gene-editing technology.

Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal

Vertex Pharmaceuticals' NaV1.8-inhibitor VX-548 measurably reduces peripheral neuropathic pain among diabetics. The drug, however, can be used to treat similar pain stemming from other health conditions.

Why Vertex Stock Is Soaring Today

The results support Vertex's hopes of developing a drug that can provide strong pain relief without the addictive potential of opioid medications.

Vertex shares pop after non-opioid painkiller posts positive mid-stage trial results

Pfizer

U.S. equities were slightly higher at midday ahead of comments from the Federal Reserve following its last meeting of the year. It's expected the central bank won't raise interest rates any further to fight inflation, and investors will also be paying attention to whether policymakers indicate any rate cuts might be coming.

Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss

Vertex solidified its potential for an alternative to opioids in pain treatment, an analyst said Wednesday. VRTX stock broke out.

Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment

Medpace Holdings

Zymeworks Inc

The pandemic pushed major biotech stocks into the spotlight as vaccine demands rose to unprecedented highs. Investors flocked to the industry in the next few years after the COVID-19 breakout.

Next Wave Biotech: 3 Stocks Poised for Breakthrough Success

Vertex Pharmaceuticals Inc. shares VRTX, +10.68% were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.

Vertex's stock heads for all-time high as non-opioid painkiller shows promise

Exact Sciences

Healthcare stocks rarely outperform the S&P 500 over long periods. Exact Sciences and Vertex Pharmaceuticals have been two of the rare exceptions over the prior 10 years.

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN). Treatment with all doses of VX-548 resulted in a statistically significant and clinically meaningful reduction in the primary endpoint of change from baseline in the weekly average of daily pain intensity on a Numeric Pain Rating Scale (NPRS) at Week 1.

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. But gene editing therapies aren't without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced two oral presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition from the global pivotal trials of CASGEVY™ (exagamglogene autotemcel [exa-cel]). Data from 96 patients (44 sickle cell disease [SCD], 52 transfusion-dependent beta thalassemia [TDT]) treated with CASGEVY in pivotal studies, with the longest follow-up of more than four years, continue to reinforce the consiste.

Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio

The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.

BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies

Axsome Therapeutics

Eli Lilly

Axsome is bringing in consistent revenue and has significant upside potential. Eli Lilly is the world's biggest drugmaker and stands to grow even more.

3 Unstoppable Stocks to Buy Right Now

Vertex and partner CRISPR Therapeutics just won FDA approval for blood disorders treatment exa-cel -- to be commercialized as Casgevy. Vertex is known for its cystic fibrosis drugs, which bring in billions of dollars in earnings annually.

Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?

The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.

The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person

The "Magnificent Seven" are all great stocks to own, but none has an actual monopoly in its field. Vertex Pharmaceuticals does have a monopoly in selling certain medicines critical to patients' health.

Forget the "Magnificent Seven": Buy This Stock Instead

Shopify

The healthcare and e-commerce industries continue to generate substantial levels of consumer spending. Vertex Pharmaceuticals just marked another landmark approval, which could be the first of multiple new blockbusters in its profitable portfolio.

2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years

The FDA has granted approval to a CRISPR-based gene editing therapy for the first time in history, validating the approach. The therapy, called Casgevy, is approved to treat Sickle Cell Disease after showing positive results in clinical trials, functionally curing patients. Despite the approval, the stock prices of CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated did not surge today, possibly due to concerns about market potential and competition from another approved therapy.

Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed

Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the first-ever gene-editing therapy using CRISPR technology in the U.S.

Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US

Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.

News for Vertex Pharmaceuticals Stock (VRTX)